Close Menu
Home › Foundation Medicine, Incyte Partner on CDx Development

Foundation Medicine, Incyte Partner on CDx Development

Sep 11, 2018

NEW YORK (GenomeWeb) – Foundation Medicine and Incyte have partnered to develop and commercialize companion diagnostics, the companies said today.

The initial focus will be on developing a CDx for Incyte's FGFR1/2/3 inhibitor, pemigatinib, to treat patients with cholangiocarcinoma. This will include the detection of activating FGFR2 translocations. The companies expect to incorporate the CDx into Foundation Medicine's existing US Food and Drug Administration-approved assay, FoundationOne CDx.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
27
Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Featured Webinar

Combining AI with Community-Driven Insights: Advanced Diagnosis of Inherited Cardiac Diseases

Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
17
Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

What's Popular?

In Cancer

  1. Illumina-Sponsored Study Finds Liquid Biopsy Complements Tissue-Based Genotyping in Lung Cancer

  2. Confirmatory Testing, Insurance Coverage Growing Alongside DTC Genetic Testing

    Premium

  3. Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests

  4. Smartphone-Based Breath Diagnostic Targets Gastric Cancer Screening

    Premium

  5. Stanford Team Uses Engineered Immune Cells as Cancer Diagnostics

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.